嵌合抗原受体T细胞治疗胶质母细胞瘤研究进展

doi:10.3969/j.issn.1672-6731.2020.02.006

摘要/Abstract

摘要：

嵌合抗原受体T细胞（CAR-T）是经基因工程改造的T细胞，能够表达肿瘤相关抗原特异性受体，特异性识别并结合肿瘤细胞。CAR-T细胞激活后可通过其细胞毒性杀灭肿瘤细胞，已在多种血液系统恶性肿瘤的治疗中获得成功，临床研究也初步显示该疗法对胶质母细胞瘤同样具有一定疗效且安全性良好，但可影响胶质母细胞瘤中T细胞的富集和功能。本文拟就CAR-T细胞疗法在胶质母细胞瘤免疫治疗中的作用机制、研究现状、挑战与展望进行综述。

关键词: 胶质母细胞瘤, T淋巴细胞, 免疫疗法, 综述

Abstract:

Chimeric antigen receptor T cell (CAR-T) is a kind of genetically engineered T cells that can express tumor-associated antigen (TAA) specific receptors on its surface. The modified T cells can be used for cancer therapy by targeting its specific receptor and killing tumor cells with its cytotoxicity. CAR-T has been successfully applied to treat many kind of hematological malignancies. Recent clinical studies have reported CAR-T cell therapy to glioblastoma. However, it can affect the enrichment and function of T cells in glioblastoma. In this review, we discuss the mechanism, research status, challenges and prospects of CAR-T cell immunotherapy for glioblastoma.

Key words: Glioblastoma, T-lymphocytes, Immunotherapy, Review

曹军, 程也, 巴特尔, 凌锋, 林庆堂. 嵌合抗原受体T细胞治疗胶质母细胞瘤研究进展[J]. 中国现代神经疾病杂志, 2020, 20(2): 105-110.

CAO Jun, CHENG Ye, BA Te-er, LING Feng, LIN Qing-tang. Clinical advances on chimeric antigen receptor T cell therapy for glioblastoma[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(2): 105-110.

http://journal11.magtechjournal.com/cjcnn/CN/Y2020/V20/I2/105

参考文献

[1] Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE, Sampson JH. Immunotherapy for malignant glioma[J]. Surg Neurol Int, 2015, 6:68-77.
[2] Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy[J]. Cancer Discov, 2018, 8:1069-1086.
[3] Lu YC, Jia L, Zheng Z, Tran E, Robbins PF, Rosenberg SA. Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy[J]. Cancer Immunol Res, 2019, 7:1824-1836.
[4] Gross G, Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment:counteracting off-tumor toxicities for safe CAR T cell therapy[J]. Annu Rev Pharmacol Toxicol, 2016, 56:59-83.
[5] Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Portnow J, D'Apuzzo M, Forman SJ, Jensen MC. Bioactivity and safety of IL13R α 2-redirected chimeric antigen receptor CD8+T cells in patients with recurrent glioblastoma[J]. Clin Cancer Res, 2015, 21:4062-4072.
[6] Filley AC, Henriquez M, Dey M. CART immunotherapy:development, success, and translation to malignant gliomas and other solid tumors[J]. Front Oncol, 2018, 8:453.
[7] Srivastava S, Riddell SR. Engineering CAR-T cells:design concepts[J]. Trends Immunol, 2015, 36:494-502.
[8] Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells[J]. J Immunol Methods, 2001, 248:67-76.
[9] Adelain M, Brentjens R, Rivibre I. The promise and potential pitfalls of chimeric antigen receptors[J]. Curr Opin Immunol, 2009, 21:215-223.
[10] Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors[J]. Curr Opin Immunol, 2015, 33:9-15.
[11] Chen D, Yang J. Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies[J]. Transl Res, 2017, 187:11-21.
[12] Jansen T, Tyler B, Mankowski JL, Recinos VR, Pradilla G, Legnani F, Laterra J, Olivi A. FasLgene knock-down therapy enhances the antiglioma immune response[J]. Neuro Oncol, 2010, 12:82-489.
[13] ButteM J, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J]. Immunity, 2007, 27:111-122.
[14] Loontz R. Breakthrough of the year 2013[J]. Science, 2013, 342:1442.
[15] Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors[J]. Clin Cancer Res, 2010, 16:474-485.
[16] Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE 2nd, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA. EGFRv Ⅲ mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss[J]. Clin Cancer Res, 2014, 20:972-984.
[17] Tu M, Wange W, Cai L, Zhu P, Gao Z, Zheng W. IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway[J]. Tumour Biol, 2016, 37:14701-14709.
[18] Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D'Apuzzo M, Barish ME, Forman SJ, Jensen MC. Stem like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells[J]. Clin Cancer Res, 2012, 18:2099-2190.
[19] Brown CE, Warden CD, Starr R, Deng X, Badie B, Yuan YC, Forman SJ, Barish ME. Glioma IL13R α 2 is associated with mesenchymal signature gene expression and poor patient prognosis[J]. PLoS One, 2013, 8:E77769.
[20] Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme:implications for targeted therapies[J]. Cancer Res, 2007, 67:7983-7986.
[21] Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B. Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J]. N Engl J Med, 2016, 375:2561-2569.
[22] Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Willisam J, Habte F, Wagner JR, Forman S, Brown C, Gambhir SS. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma[J]. Sci Transl Med, 2017, 9:eaag2196.
[23] Brown MP, Ebert LM, Gargett T. Clinical chimeric antigen receptor-T cell therapy:a new and promising treatment modality for glioblastoma[J]. Clin Transl Immunology, 2019, 8:E1050.
[24] Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma:a phase 1 dose-escalation trial[J]. JAMA Oncol, 2017, 3:1094-1101.
[25] Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM. CAR T-cell therapy for glioblastoma:recent clinical advances and future challenges[J]. Neuro Oncol, 2018, 20:1429-1438.
[26] Li G, Wong AJ. EGF receptor variant Ⅲ as a target antigen for tumor immunotherapy[J]. Expert Rev Vaccines, 2008, 7:977-985.
[27] Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA. Recognition of glioma stem cells by genetically modified T cells targeting EGFRv Ⅲ and development of adoptive cell therapy for glioma[J]. Hum Gene Ther, 2012, 23:1043-1053.
[28] Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT Ⅳ Trial Investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRv Ⅲ-expressing glioblastoma (ACT Ⅳ):a randomised, double-blind, international phase 3 trial[J]. Lancet Oncol, 2017, 18:1373-1385.
[29] O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJ, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRv Ⅲ-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma[J]. Sci Transl Med, 2017, 9:aaa0984.
[30] Del Vecchio CA, Giacomini CP, Vogel H, Jensen KC, Florio T, Merio A, Pollack JR, Wong AJ. EGFRv Ⅲ gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms[J]. Oncogene, 2013, 32:2670-2681.
[31] Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, Kamp M, Sabel M, Simon M, Westphal M, Schackert G, Tonn JC, Pietsch T, von Deimling A, Loeffler M, Reifenberger G, Weller M; German Glioma Network. Prognostic role of epidermal growth factor receptor variant Ⅲ(EGFRv Ⅲ) positivity in EGFR-amplified primary and recurrent glioblastomas[J]. Clin Cancer Res, 2017, 23:6846-6855.
[32] Newick K, O'Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors[J]. Annu Rev Med, 2017, 68:139-152.
[33] Mirzaei R, Sarkar S, Yong VW. T cell exhaustion in glioblastoma:intricacies of immune checkpoints[J]. Trends Immunol, 2017, 38:104-115.
[34] Hao C, Parney IF, Roa WH, Turner J, Petruk KC, Ramsay DA. Cytokine and cytokine receptor mRNA expression in human glioblastomas:evidence of Th1, Th2 and Th3 cytokine dysregulation[J]. Acta Neuropathol, 2002, 103:171-178.
[35] Wei J, Wu A, Kong LY, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB. Hypoxia potentiates glioma-mediated immunosuppression[J]. PLoS One, 2011, 6:E16195.
[36] Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, Singh SK. Intratumoral heterogeneity:pathways to treatment resistance and relapse in human glioblastoma[J]. Ann Oncol, 2017, 28:1448-1456.
[37] Aubry M, Tayrac MD, Etcheverry A, Clavreul A, Saikali S, Menei P, Mosser J. From the core to beyond the margin:a genomic picture of glioblastoma intratumor heterogeneity[J]. Oncotarget, 2015, 6:12094-12109.
[38] Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma[J]. Haematologica, 2016, 101:616-625.

选择文件类型/文献管理软件名称

选择包含的内容

2 嵌合抗原受体T细胞治疗胶质母细胞瘤研究进展

Clinical advances on chimeric antigen receptor T cell therapy for glioblastoma

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛蓉, 张轩. 睡眠障碍对脑血管病的影响[J]. 中国现代神经疾病杂志, 2023, 23(8): 659-662.
[2]	张鹏, 陈涛, 许莉. 成人失眠认知行为疗法关键技术与流程改进建议[J]. 中国现代神经疾病杂志, 2023, 23(8): 663-667.
[3]	张轩, 薛蓉. 特发性快速眼动睡眠期行为障碍向神经系统变性疾病转化的生物学标志物研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 668-673.
[4]	刘引, 汤永红, 翟锦霞, 邱媛. 慢性低度炎症与睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 674-677.
[5]	于洁洋, 张亚男, 李惠敏, 黄真灿, 李宛儒, 王赞. 发作性睡病与焦虑研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 678-682.
[6]	库成心, 邓丽影, 谢亮. 缺血性卒中继发日间过度思睡研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 683-686.
[7]	姜佳凤, 赵莲花, 赵伟. 褪黑素在阿尔茨海默病病理损害机制中的作用[J]. 中国现代神经疾病杂志, 2023, 23(8): 687-692.
[8]	黄沛, 王刚. 功能性帕金森综合征诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(8): 738-741.
[9]	任修德, 李涛, 范吉康, 王希森, 贾晓丹, 杨学军. 胶质母细胞瘤FGFR3-TACC3融合基因介导丙酮酸激酶M2入核促进DNA损伤修复基础研究[J]. 中国现代神经疾病杂志, 2023, 23(8): 745-757.
[10]	洪涛, 唐斌. 如何成为一名优秀的颅底外科医师[J]. 中国现代神经疾病杂志, 2023, 23(7): 571-574.
[11]	张庆硕, 宋丹丹, 周世越, 张金璐, 韩晓旭, 许顺良. 功能性步态障碍诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(7): 604-609.
[12]	潘希娟, 邢英琦, 刘玉梅. 脑小血管病影像学评分方法[J]. 中国现代神经疾病杂志, 2023, 23(7): 633-637.
[13]	俞淑凤, 李宁, 徐健, 王鹏. 颈动脉漂浮血栓相关缺血性卒中诊断与治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(7): 638-642.
[14]	魏俊吉. 神经外科重症医学规范化诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(6): 477-478.
[15]	杜倩, 邓素君, 邹姗, 金珺, 周青山. 宏基因组第二代测序技术在重症中枢神经系统感染中的应用[J]. 中国现代神经疾病杂志, 2023, 23(6): 479-484.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 嵌合抗原受体T细胞治疗胶质母细胞瘤研究进展

Clinical advances on chimeric antigen receptor T cell therapy for glioblastoma

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价